Search results for "Ibd"

showing 10 items of 96 documents

Infliximab and emerging biological treatment for pediatric Crohn’s disease.

2009

Infliximab IBD Pediatric onset
researchProduct

1001 infusions of Infliximab in children with IBD: a 10 years study from the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition

2009

Infliximab Pediatric IBD
researchProduct

LU Bibliotēka saņem atzinību par dalību projektā LibdayLV 2017

2017

Latvijas Universitātes (LU) Bibliotēka visas vasaras garumā piedalījās projektā “Viena diena bibliotēkas dzīvē” jeb interneta vidē atpazīstams kā LibdayLV. Projektu jau 7. reizi rīkoja Latvijas Bibliotekāru biedrības Jauno speciālistu sekcija (LBB JSS) ar mērķi popularizēt bibliotekāra profesiju un lauzt stereotipus. LU Bibliotēka saņēma atzinību par dalību šajā projektā.

LibdayLV 2017bibliotekāra profesijaLU Bibliotēka:SOCIAL SCIENCES::Other social sciences::Library and information science [Research Subject Categories]
researchProduct

ANALISI DEL RUOLO DI MEDIATORI ENTERICI NELLA FISIOPATOLOGIA DELLE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI

MICI IBD Inflammatory Bowel Disease Enteric Nervous System Inflammation Gastrointestinal Angiotensin GABA
researchProduct

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory …

2011

See related article, Oostlander AE et al, on page 116 in Gastroenterology. BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and benefits of therapy with tumor necrosis factor (TNF) inhibitors in these patients. METHODS: We collected data from patients with IBD treated with infliximab (n 2475) and adalimumab (n 604) from 2000 to 2009 at 16 tertiary centers. Ninety-five patients (3%) were more than 65 years old (52 men; 37 with ulcerative colitis and 58 with Crohn’s disease; 78 treated with infliximab and 17 with adalimumab). The control group comprised 190 patients 65 yea…

MaleAgingSettore MED/09 - Medicina InternaBiologicantagonists /&/ inhibitors/immunology Young AdultInflammatory bowel diseaseHumanized AntibodieElderlyNeoplasmsMonoclonalYoung adultAged 80 and overSettore MED/12 - GastroenterologiaCrohn's diseaseGastroenterologyAge FactorsAntibodies MonoclonalMiddle AgedUlcerative colitisepidemiology Opportunistic InfectionFemaleDrug ComplicationSafetymedicine.drugAdultmedicine.medical_specialtyAdolescentIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedYoung AdultInternal medicinemedicineAdalimumab80 and over AntibodieHumansImmunologic FactorsRisk factoradverse effects/therapeutic use Inflammatory Bowel DiseaseAgedHepatologymortality/therapy Male Middle Aged Neoplasmepidemiology Tumor Necrosis Factor-alphabusiness.industryTumor Necrosis Factor-alphaAdalimumabmedicine.diseaseInflammatory Bowel DiseasesCrohn's Disease Activity IndexInfliximabInfliximabSurgeryInflammation Side Effects Drug ComplicationsSide Effectinflammationadverse effects/therapeutic use Female Humans Immunologic FactorAdolescent Adult Age Factors Aged Agedbusiness
researchProduct

Probiotic mixture supplementation in the preventive management of trinitrobenzenesulfonic acid-induced inflammation in a murine model

2016

Inflammatory bowel diseases (IBD) are characterized by inflammatory conditions of the intestine. Probiotic bacteria (PB) can have beneficial effects in several gastrointestinal disorders. The objectives of this study were: (i) to provide an acute experimental IBD model induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in CD-1 mice, and (ii) to assess the preventive effects of Citogenex (Lactobacillus casei and Bifidobacterum lactis) supplementation on intestinal tissues and microbiota. Mice were inoculated intrarectally with saline, ethanol or different TNBS solutions. 1%TNBS induced clinical signs of colitis (P less than 0.01) and histological damage (P less than 0.01). Based on these r…

MaleColonProbioticsColitisInflammatory Bowel Diseasesdigestive systemdigestive system diseasesGastrointestinal MicrobiomeIBD ProbioticsDisease Models AnimalLacticaseibacillus caseiMiceBifidobacterium animalisTrinitrobenzenesulfonic AcidAnimals Outbred StrainsAnimalsIBD probioticinduced-colitis model disease activity index microbiota
researchProduct

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

2020

Abstract Background Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margi…

MaleOncologyColorectal cancerDNA Mismatch RepairCOLORECTAL-CANCERSettore MED/120302 clinical medicinePMS2small bowel adenocarcinomaMismatch Repair Endonuclease PMS20303 health sciencesPrognosisMMRMutS Homolog 2 ProteinOncologyCARCINOMAS030220 oncology & carcinogenesisimmunohistochemistryMismatch Repair Status small bowel adenocarcinomaFemaleMicrosatellite InstabilityDNA mismatch repairMutL Protein Homolog 1Colorectal Neoplasmsstage IImedicine.medical_specialtyhigh-risk pathologic featuresDNA Mismatch Repair; Female; Humans; Male; Microsatellite Instability; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Prognosis; Adenocarcinoma; Colorectal Neoplasmssmall bowel adenocarcinoma; mismatch repair statusAdenocarcinomaNO03 medical and health sciencessmall bowel carcinomahistotypeInternal medicineTranslational ResearchmedicineHumansmismatch repair status030304 developmental biologysmall bowel adenocarcinomasbusiness.industryCancerMicrosatellite instabilityMismatch Repair ProteinAdenocarcinoma IBD Cancermedicine.diseasedigestive system diseasesMSH6COLORECTAL-CANCER; CARCINOMAS; CONSENSUSsmall bowel carcinoma MMR immunohistochemistryMismatch repair Small bowel AdenocarcinomaMSH2Mismatch repair status; stage II; small bowel adenocarcinomas; histotype; high-risk pathologic featuresSurgeryCONSENSUSbusiness
researchProduct

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease

2011

Objectives: Loss of intestinal barrier function plays an important role in the pathogenesis of inflammatory bowel disease (IBD). Shedding of intestinal epithelial cells is a potential cause of barrier loss during inflammation. The objectives of the study were (1) to determine whether cell shedding and barrier loss in humans can be detected by confocal endomicroscopy and (2) whether these parameters predict relapse of IBD. Methods: Confocal endomicroscopy was performed in IBD and control patients using intravenous fluorescein to determine the relationship between cell shedding and local barrier dysfunction. A grading system based on appearances at confocal endomicroscopy in humans was devise…

MalePathologyfluoresceintight junctionPilot ProjectsCrohn's DiseaseInflammatory bowel diseaseGastroenterologyEndoscopy Gastrointestinaltumour necrosis factor0302 clinical medicineIntestinal mucosaRecurrencecolonoscopyMedizinische Fakultätgut differentiationProspective Studies1506Intestinal MucosaConfocal laser endomicroscopyIBD modelsBarrier function0303 health sciencesCrohn's diseaseMicroscopy ConfocalapoptosisGastroenterologyMiddle AgedPrognosisUlcerative colitisBarrett's oesophagus3. Good healthcell deathDisease ProgressionFemalecell shedding030211 gastroenterology & hepatologyBarrett's metaplasiagastrointestinal physiologyAdultmedicine.medical_specialtySubsequent RelapseConfocalcolorectal cancer-mucosal healing03 medical and health sciencesPredictive Value of Testscolorectal metastasesInternal medicinegastrinmedicineEndomicroscopyHumansddc:610endoscopyFluorescent Dyesulcerative colitis030304 developmental biologymagnifying colonoscopybusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseasesmedicine.diseaseIBD basic researchbarrier functionbusiness
researchProduct

Use of Hydrogen Molybdenum Bronze in Vacuum‐Deposited Perovskite Solar Cells

2019

Herein, the dehydration of a hydrogen molybdenum bronze (HYMoO3), converting it to molybdenum oxide (MoOX), is explored toward the development of perovskite solar cells (PSCs) for the first time. H0.11MoO3 bronze is synthesized, characterized, and deposited on indium tin oxide (ITO) under different concentrations and annealing conditions for in situ conversion into MoOX with appropriate oxygen vacancies. Vacuum‐deposited PSCs are fabricated using the as‐produced MoOX hole injection layers, achieving a power conversion efficiency of 17.3% (average) for the optimal device. The latter has its stability and reproducibility tested, proving the robustness and affordability of the developed hole t…

Materials scienceHydrogenMetallurgyMolybdenum oxidechemistry.chemical_elementMolybdenum bronzechemistry.chemical_compoundGeneral EnergychemistryMOLIBDÊNIOMaterialsCèl·lules fotoelèctriquesPerovskite (structure)
researchProduct

Molecular Passivation of MoO3: Band Alignment and Protection of Charge Transport Layers in Vacuum-Deposited Perovskite Solar Cells

2019

Vacuum-deposition of perovskite solar cells can achieve efficiencies rivalling solution-based methods and it allows for more complex device stacks. MoO3 has been used to enhance carrier extraction to the transparent bottom electrode in a p-i-n configuration, here we show that by inserting an organic charge transport molecule it can also be used on the top of a perovskite absorber in a n-i-p configuration. This strategy enables the first vacuum-deposited perovskite solar cells with metal oxides as charge transporting layers for both electrons and holes leading to power conversion efficiency > 19 %.

Materials sciencePassivationbusiness.industryGeneral Chemical EngineeringExtraction (chemistry)Charge (physics)02 engineering and technologyGeneral Chemistry010402 general chemistry021001 nanoscience & nanotechnology01 natural sciences0104 chemical sciencesVacuum depositionMaterials ChemistryOptoelectronicsMOLIBDÊNIO0210 nano-technologybusinessMaterialsCèl·lules fotoelèctriquesPerovskite (structure)
researchProduct